Barclays PLC Acquires 46,783 Shares of RxSight, Inc. (NASDAQ:RXST)

Barclays PLC lifted its stake in RxSight, Inc. (NASDAQ:RXST) by 389.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 58,786 shares of the company’s stock after buying an additional 46,783 shares during the period. Barclays PLC’s holdings in RxSight were worth $2,906,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Amalgamated Bank boosted its holdings in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares during the period. Principal Financial Group Inc. grew its position in RxSight by 0.7% during the third quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock worth $1,782,000 after buying an additional 240 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in RxSight by 3.2% during the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock worth $473,000 after buying an additional 242 shares in the last quarter. Quarry LP increased its stake in RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after acquiring an additional 288 shares during the period. Finally, Arizona State Retirement System raised its holdings in RxSight by 5.0% in the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock valued at $467,000 after acquiring an additional 373 shares in the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight Stock Down 0.3 %

NASDAQ:RXST opened at $34.47 on Wednesday. The firm has a market cap of $1.39 billion, a PE ratio of -41.53 and a beta of 1.11. RxSight, Inc. has a 12 month low of $33.03 and a 12 month high of $66.54. The company’s 50-day moving average price is $45.44 and its two-hundred day moving average price is $49.81.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Stifel Nicolaus lowered RxSight from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $65.00 to $40.00 in a report on Friday, December 20th. Jefferies Financial Group assumed coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target on the stock. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $42.00 price objective (down from $56.00) on shares of RxSight in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Finally, UBS Group assumed coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 price target for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $59.00.

Insider Activity

In related news, insider Ilya Goldshleger sold 3,105 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $51.91, for a total transaction of $161,180.55. Following the completion of the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,192,989.86. This trade represents a 6.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Shweta Maniar sold 3,782 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the transaction, the director now directly owns 10,902 shares in the company, valued at approximately $500,183.76. This represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,607 shares of company stock worth $2,874,109. Insiders own 9.36% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.